Physician profile
Kirk M Uomoto
NPI 1578510426
$1,543.07
in general payments reported to CMS, 2019-2025
24 companies · $478 in 2025
The $478 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $32.86 · 2021: $166 · 2022: $175 · 2023: $189 · 2024: $364 · 2025: $478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,030.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $251.15 | 2021-2025 | Farxiga, Lokelma |
| Janssen Pharmaceuticals, INC | $232.45 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $141.13 | 2019-2025 | Mounjaro, Kisunla |
| Novartis Pharmaceuticals Corporation | $101.70 | 2023-2025 | |
| Lundbeck LLC | $98.45 | 2023-2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $93.42 | 2023-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.62 | 2024-2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.67 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.89 | 2023-2025 | Xifaxan, Relistor |
| Bayer Healthcare Pharmaceuticals INC. | $53.76 | 2024 | |
| Novo Nordisk INC | $39.24 | 2021 | |
| Astellas Pharma US INC | $39.13 | 2019-2021 | |
| Medtronic, INC. | $35.45 | 2022 | |
| Kite Pharma, INC. | $33.59 | 2025 | Yescarta |
| Pfizer INC. | $33.03 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $28.49 | 2021 | |
| Janssen Scientific Affairs, LLC | $25.13 | 2021 | |
| Mannkind Corporation | $24.91 | 2025 | |
| Gilead Sciences, INC. | $23.91 | 2025 | |
| Dexcom, INC. | $23.29 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $21.41 | 2025 | Eliquis |
| Abbvie INC. | $17.52 | 2019 | |
| Scilex Pharmaceuticals INC. | $16.34 | 2020 | |
| Allergan, INC. | $12.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kirk Uomoto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.